A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Open to people ages 18 years and up

• Participants must have relapsed or refractory multiple myeloma (RRMM).
• Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody, and be refractory to lenalidomide (LEN) (progression on or within 60 days of completing LEN therapy).
• Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
• Participants must have measurable disease during screening.
• Participants must have adequate organ function.
• Participants must have an Eastern Cooperative Oncology group performance status 0 or

• Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
• Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
• Participants must not need urgent treatment due to rapidly progressing MM.
• Other protocol-defined Inclusion/Exclusion criteria apply.